Health and bio · United States · founded 2022
OpenEvidence valuation and IPO status
OpenEvidence is valued at $15B (21 Oct 2026). IPO status: private.
Source tier: ReportedSource: Ars Technica
Information only, not investment advice. Figures are from public sources; tiers show how solid each one is.
About OpenEvidence
AI search and answer tool for doctors, free to clinicians and funded by pharmaceutical and medical advertising.
Valued at $15B as of September 2026 per Wikipedia's summary of this report; round details not checked.
OpenEvidence valuation history
Priced transactions, newest to the right
Show the data
| Date | Event | Valuation | Tier | Source |
|---|---|---|---|---|
| primary round | $15B | Source tier: Reported | Ars Technica | |
| primary round | $12B | Source tier: Reported | The Economic Times | |
| primary round | $6B | Source tier: Reported | The New York Times | |
| primary round | $3.5B | Source tier: Reported | Modern Healthcare | |
| primary round | $1B | Source tier: Reported | CNBC |
Key investors
Sequoia Capital, GV, Kleiner Perkins.
OpenEvidence: quick answers
How much is OpenEvidence worth?
OpenEvidence's latest priced valuation is $15B (21 Oct 2026), according to Ars Technica. We label it reported.
Is OpenEvidence going public?
Status: private.
Who invests in OpenEvidence?
Named investors include Sequoia Capital, GV, Kleiner Perkins.
Sources
- Ars Technica. arstechnica.com, Source tier: Reported
- The Economic Times. enterpriseai.economictimes.indiatimes.com, Source tier: Reported
- The New York Times. nytimes.com, Source tier: Reported
- Modern Healthcare. modernhealthcare.com, Source tier: Reported
- CNBC. cnbc.com, Source tier: Reported